Washington, D.C. 20549


                                    FORM 6-K


                            REPORT OF FOREIGN ISSUER

                       Pursuant to Rule 13a-16 or 15d-16
                     of the Securities Exchange Act of 1934

                                  APRIL 01 2005


                                NOVO NORDISK A/S
             (Exact name of Registrant as specified in its charter)

                                    NOVO ALLE
                               DK-2880, BAGSVAERD
                    (Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

                       Form 20-F [X]     Form 40-F [ ]

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes [ ]     No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________



In continuation of the company's announcement on 30 April 2004 of a planned
share repurchase programme, and pursuant to Section 29 of the Danish Securities
Trading Act and Section 204.33 of the New York Stock Exchange Listed Company
Manual, this is to report that as of today, Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates owns 23,174,069 of its own B shares of DKK 2,
corresponding to a total nominal value of DKK 46,348,138 or 6.53% of the total
share capital.

In the first quarter of 2005 a total of 715,000 B shares were repurchased by
Novo Nordisk A/S, and 126,060 B shares were disposed of to employees who
exercised options granted by Novo Nordisk.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time
employees in 78 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.

For further information please contact:

Media:                         Investors:
Outside North America:         Outside North America:

Elin K Hansen                  Mogens Thorsager Jensen
Tel (direct):                  Tel (direct):
(+45) 4442 3450                (+45) 4442 7945

                               Palle Holm Olesen

                               Tel (direct):

                               (+45) 4442 6175

In North America:              In North America:

Susan T Jackson                Mads Veggerby Lausten
Tel (direct):                  Tel (direct):
(+1) 609 919 7776              (+45) 4443 7919

Stock Exchange Announcement No 14/2005


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf of the
undersigned, thereunto duly authorized.

Date: APRIL 01 2005                            NOVO NORDISK A/S
                                            Lars Rebien Sorensen,
                                     President and Chief Executive Officer